We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A clinical trial has been conducted to use the Chinese-produced sintilimab as a second-line therapy for advanced ESCC and has achieved positive results.